Diapin's Promising Drug Candidate, DT109, was Featured in ScienceDaily for the Potential Treatment of Metabolic Dysfunction-Associated Steatopepatitis (MASH)

October 17, 2026 

​​

We are thrilled to share that Diapin Therapeutics Inc's promising drug candidate, DT109, was featured in ScienceDaily for the potential treatment of metabolic dysfunction-associated steatohepatitis (MASH)!

​

New research at University of Michigan suggests that DT109 may help protect the liver by restoring the gut microbiome's protective barrier, reducing harmful gut bacteria, and reducing inflammation. 

​

We would like to thank Dr. Eugene Chen and his team for this important work and look forward to advancing this promising research of novel therapeutics for cardiometabolic disease.

​

Read News: https://www.sciencedaily.com/releases/2026/10/261016080912.htm